Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today announced results from new post hoc analyses of the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic ...
A four-month investigation with Channel 4 News reveals harrowing failings at one of Britain's most prestigious hospitals ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback